1-3 of 3
Tom Lillie, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD
Journal: Blood
Blood (2006) 108 (11): 1306.
https://doi.org/10.1182/blood.V108.11.1306.1306
Published: 2006
Journal Articles

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

David H. Gordon, MD, Gwen Nichols, MD, Ali Ben-Jacob, MD, Hung Lam, PhD, Tom Lillie, MD, PhD, Carole Miller, MD
Journal: Blood
Blood (2006) 108 (11): 1304.
https://doi.org/10.1182/blood.V108.11.1304.1304
Published: 2006
Journal Articles

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Jean-Luc Canon, MD, Johan Vansteenkiste, MD, Gyorgy Bodoky, MD, Ma Victoria Mateos, MD, Laurent Bastit, MD, Irene Ferreira, PhD, Tom Lillie, MD
Journal: Blood
Blood (2005) 106 (11): 3558.
https://doi.org/10.1182/blood.V106.11.3558.3558
Published: 2005